Research Analysts Offer Predictions for Teladoc Health, Inc.’s Q3 2024 Earnings (NYSE:TDOC)

Teladoc Health, Inc. (NYSE:TDOC) – Equities researchers at Zacks Research decreased their Q3 2024 earnings per share (EPS) estimates for shares of Teladoc Health in a research note issued to investors on Tuesday, September 3rd. Zacks Research analyst D. Chatterjee now anticipates that the health services provider will earn ($0.34) per share for the quarter, down from their prior forecast of ($0.28). The consensus estimate for Teladoc Health’s current full-year earnings is ($0.71) per share. Zacks Research also issued estimates for Teladoc Health’s Q4 2024 earnings at ($0.20) EPS, FY2024 earnings at ($1.31) EPS, Q1 2025 earnings at ($0.42) EPS, Q2 2025 earnings at ($0.33) EPS, Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($1.16) EPS, Q1 2026 earnings at ($0.39) EPS, Q2 2026 earnings at ($0.24) EPS and FY2026 earnings at ($0.97) EPS.

Teladoc Health (NYSE:TDOC) last posted its quarterly earnings results on Wednesday, July 31st. The health services provider reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.08. The company had revenue of $642.44 million for the quarter, compared to the consensus estimate of $649.34 million. Teladoc Health had a negative return on equity of 10.25% and a negative net margin of 38.54%.

A number of other research analysts also recently weighed in on the company. Piper Sandler cut their price target on Teladoc Health from $25.00 to $10.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 6th. Bank of America lowered their price objective on shares of Teladoc Health from $16.50 to $13.50 and set a “neutral” rating for the company in a research report on Tuesday, May 14th. Evercore ISI lowered their price objective on shares of Teladoc Health from $14.00 to $10.00 and set an “in-line” rating for the company in a research report on Tuesday, July 9th. Oppenheimer lowered their price objective on shares of Teladoc Health from $21.00 to $17.00 and set an “outperform” rating for the company in a research report on Thursday, August 1st. Finally, TD Cowen lowered their price objective on shares of Teladoc Health from $15.00 to $9.00 and set a “hold” rating for the company in a research report on Thursday, August 1st. Fourteen research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $12.44.

Teladoc Health Stock Performance

TDOC stock opened at $7.67 on Friday. The business’s fifty day moving average is $8.29 and its 200-day moving average is $11.52. The company has a quick ratio of 1.62, a current ratio of 1.66 and a debt-to-equity ratio of 0.66. The company has a market cap of $1.30 billion, a P/E ratio of -5.44 and a beta of 0.90. Teladoc Health has a twelve month low of $6.76 and a twelve month high of $23.05.

Hedge Funds Weigh In On Teladoc Health

A number of large investors have recently modified their holdings of TDOC. ICA Group Wealth Management LLC acquired a new position in shares of Teladoc Health during the 4th quarter worth about $28,000. Signaturefd LLC boosted its stake in shares of Teladoc Health by 148.7% during the 2nd quarter. Signaturefd LLC now owns 2,868 shares of the health services provider’s stock worth $28,000 after buying an additional 1,715 shares during the last quarter. International Assets Investment Management LLC acquired a new stake in Teladoc Health in the 2nd quarter valued at about $29,000. Principal Securities Inc. acquired a new stake in Teladoc Health in the 4th quarter valued at about $45,000. Finally, Doheny Asset Management CA acquired a new stake in Teladoc Health in the 2nd quarter valued at about $46,000. 76.82% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Teladoc Health news, insider Vidya Raman-Tangella sold 3,857 shares of the stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $8.14, for a total transaction of $31,395.98. Following the completion of the transaction, the insider now owns 33,667 shares in the company, valued at approximately $274,049.38. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, insider Vidya Raman-Tangella sold 3,857 shares of the stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $8.14, for a total transaction of $31,395.98. Following the completion of the transaction, the insider now directly owns 33,667 shares in the company, valued at approximately $274,049.38. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Mala Murthy sold 8,750 shares of the stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $7.16, for a total transaction of $62,650.00. Following the transaction, the chief financial officer now owns 85,767 shares of the company’s stock, valued at $614,091.72. The disclosure for this sale can be found here. In the last 90 days, insiders sold 57,819 shares of company stock worth $442,204. Corporate insiders own 0.95% of the company’s stock.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.